1. High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects 
William Busse, MD, Sheldon Spector, MD, Karin Rosén, MD, PhD, Yan Wang, PhD, MPH, Oral Alpan, MD 
Journal of Allergy and Clinical Immunology 
Volume 132, Issue 2, Pages e11 (August 2013)
DOI: /j.jaci
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Rate ratio (95% CI) of protocol-defined asthma exacerbation by subgroup.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig E1
Patient disposition. ∗Five patients were found to be ineligible after enrollment.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig E2
Least squares means of relative change from baseline in FEV1 (mITT population [excluding 1 patient with outlying spirometry data]). LSM, Least squares means (adjusted for dosing regimen and prior exacerbation status). *P = .04; †P = .002; ‡P = .02; **P = .008.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Fig E3
Rate ratio (95% CI) of protocol-defined asthma exacerbation by prior exacerbation status and dosing regimen subgroups. Q2, every 2 wk; Q4, every 4 wk.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Fig E4
Least squares means of relative change from baseline in FEV1 (mITT population). LSM, Least squares means (adjusted for dosing regimen and prior exacerbation status). *P = .02; †P = .001; ‡P = .01; **P = .009.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions